GRASSO MARC 4

4 · Kyverna Therapeutics, Inc. · Filed Mar 17, 2026

AI-generated summary of this filing

Updated Mar 17, 2026

Kyverna (KYTX) CFO Marc Grasso Receives RSUs & Option Grant

What Happened

Marc Grasso, Chief Financial Officer of Kyverna Therapeutics (KYTX), received equity awards on March 13, 2026: 10,000 restricted stock units (RSUs) and a 65,000-share option award (reported as a derivative). Both grants show $0.00 as the acquisition price on the Form 4 (i.e., these are company awards, not open‑market purchases).

Key Details

Transaction date: March 13, 2026; Form 4 filed March 17, 2026 (filing appears timely).
Awards: 10,000 RSUs (@ $0.00) and 65,000 derivative shares (option award) (@ $0.00).
Vesting (per footnotes): RSUs — 1/4 vest on March 13, 2027 and 1/4 each year thereafter; Options — 1/4 vest on March 13, 2027 and then 1/48 each month thereafter, subject to continued service.
Shares owned after transaction: Not specified in the provided filing excerpt.
Transaction code: A = Award/Grant; derivative entry indicates an option grant (not an exercise or sale).

Context

These are compensatory equity grants (awards), not purchases or sales, and do not indicate immediate cash proceeds. The option award is a derivative security subject to vesting; it was granted, not exercised. Such grants are common for executive compensation and are contingent on continued service and future vesting.

Form 4

Period: 2026-03-13

Chief Financial Officer

Transactions

Award
Common Stock
[F1]
2026-03-13+10,000→ 10,000 total
Award
Stock Option (right to buy)
[F2]
2026-03-13+65,000→ 65,000 total
Exercise: $8.95Exp: 2036-03-13→ Common Stock (65,000 underlying)

Footnotes (2)

[F1]Represents a restricted stock unit award of common stock and 1/4th of the shares underlying the restricted stock unit award shall vest on March 13, 2027 and an additional 1/4th of the shares underlying the restricted stock unit award shall vest on each one-year anniversary thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.
[F2]1/4th of the shares subject to the option shall vest on March 13, 2027 and an additional 1/48th of the shares subject to the option shall vest on the same day of each month thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.

Signature

By: /s/ Marc Grasso|2026-03-17

1 file